KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Edwards Lifesciences (EW) Cash from Operations (2016 - 2025)

Edwards Lifesciences has reported Cash from Operations over the past 17 years, most recently at 450900000.0 for Q4 2025.

  • Quarterly results put Cash from Operations at 450900000.0 for Q4 2025, up 453.65% from a year ago — trailing twelve months through Dec 2025 was 1595200000.0 (up 194.15% YoY), and the annual figure for FY2025 was 1595200000.0, up 194.15%.
  • Cash from Operations for Q4 2025 was 450900000.0 at Edwards Lifesciences, down from 573700000.0 in the prior quarter.
  • Over the last five years, Cash from Operations for EW hit a ceiling of 573700000.0 in Q3 2025 and a floor of 127500000.0 in Q4 2024.
  • Median Cash from Operations over the past 5 years was 312000000.0 (2022), compared with a mean of 299180000.0.
  • Peak annual rise in Cash from Operations hit 1005.65% in 2024, while the deepest fall reached 193.34% in 2024.
  • Edwards Lifesciences' Cash from Operations stood at 373600000.0 in 2021, then dropped by 24.3% to 282800000.0 in 2022, then plummeted by 51.7% to 136600000.0 in 2023, then tumbled by 193.34% to 127500000.0 in 2024, then surged by 453.65% to 450900000.0 in 2025.
  • The last three reported values for Cash from Operations were 450900000.0 (Q4 2025), 573700000.0 (Q3 2025), and 290200000.0 (Q2 2025) per Business Quant data.